GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
Novo-Nordisk A/S faces another blow: Musk shares a weight loss photo, claiming that using Eli Lilly and Co's weight loss drug is more effective than semaglutide.
On Christmas, Musk shared a photo and called himself the Ozempic Santa Claus, clarifying that he didn't mean the drug name Ozempic for semaglutide, but rather Eli Lilly and Co's competitor Mounjaro. He also mentioned that "high doses" of Ozempic would make him fart and burp, adding that "Mounjaro seems to have fewer side effects and is more effective."
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
Top Dividend Picks for 2025 According to Seeking Alpha's Quant Metrics
Musk revealed that he switched to using Eli Lilly and Co's weight loss medication: the effect is better than Novo-Nordisk A/S's competing products, with fewer side effects.
① The world's richest man Elon Musk confirmed on the Social Media platform X on Wednesday that he is using Eli Lilly and Co's Mounjaro for weight loss; ② Musk revealed that he initially tried using Novo-Nordisk A/S's Ozempic for weight loss, but switched to Mounjaro due to significant side effects.
10 Health Care Stocks With Whale Alerts In Today's Session
Elon Musk Says He Prefers Lilly's Mounjaro Over Novo's Ozempic
iG68 : u think will be lower when the market open?
pootpoot OP iG68 : no idea. hourly chart theres 4 attempts to break 90. failed. technically, nvo is in complete bear trend. below all moving averages. so if it doesnt break 90.. likely a pullback